biote Corp.

biote Corp. (Nasdaq: BTMD) is a healthcare company specializing in hormone optimization, offering training, certification, and practice-support services to clinicians who administer subcutaneous pellet therapy. The company completed its de-SPAC transaction in 2022, merging with Haymaker Acquisition Corp. II, a blank-check vehicle sponsored by Haymaker Capital Management that completed its IPO in 2020. A Form 10-Q filed in May 2021 reflects the company's financial disclosures during the pre-merger period, providing a snapshot of operations ahead of the business combination's close. biote operates in the specialty healthcare and physician practice management sector. For comprehensive filing timelines, sponsor profiles, and deal analytics on BTMD, sign up for full data access at SpacDesk.